linjc16/ctgov huggingface dataset:
Effect of Drainage on Laparoscopic Gastric Bypass Surgery

Study Overview
=================
Brief Summary
-----------------
Introduction RYGB surgeon; Have become increasingly morbid obesity treatment methods with improvements in minimally invasive surgery. Ensuring patient comfort and early return to life are the criteria that should be given priority in this treatment method. The purpose of this study is to determine the use of drain, which closely affects these criteria; And the effect on patient comfort.

Detailed Description
-----------------
Question the necessity of routine use of drain in RYGB surgeon

Official Title
-----------------
Effect of Drain Usage on Patient Comfort on Laparoscopic Gastric Bypass Surgery

Conditions
-----------------
Obesity, Morbid

Intervention / Treatment
-----------------
* Other: Drainage


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Morbid obese patients Exclusion Criteria: Cirrhotic patients, those under 18 years of age, additional intraabdominal surgeries during LRYGBP and those who had previously undergone obesity surgery (revision surgery) were excluded

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: DRAIN PLACEMENT<br>Effects of drainage | Other: Drainage<br>* Using drain after operation<br>|
| No Intervention: DRAIN NOT PLACED<br>Effects of not using drain | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 3-Item Pain Intensity measyre (P3) | self reported pain intensity morning, second day and third day. Each item is scored 0-10 ( 0: no pain- 10: pain as bad as can be) | 8 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Obesity, VAS, Pain, Laparoscopy, Bypass
Prospective Assessment Project About Cardiac Arrest Resuscitation

Study Overview
=================
Brief Summary
-----------------
In case of a cardiac arrest it is very important to quickly provide high quality cardiopulmonary resuscitation (CPR). For reasons of patient safety the investigators want to assess the frequency, the quality and the outcome of cardiopulmonary resuscitations in the Inselspital Bern.

Official Title
-----------------
Prospective Assessment Project About Cardiac Arrest Resuscitation

Conditions
-----------------
Cardiac Arrest

Intervention / Treatment
-----------------
* Procedure: Cardiopulmonary resuscitation (CPR)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Every patient for which the alarm button for a cardiopulmonary arrest gets triggered Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Cardiopulmonary resuscitation (CPR)|If there is a cardiopulmonary arrest, investigators observe the working processes of cardiopulmonary resuscitation.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of reanimation alarms during a time period of 1 year. |  | up to 1 year |
Role of FDG PET, Immune and Hypoxic Marker in NSCLC

Study Overview
=================
Brief Summary
-----------------
This is a retrospective study that involves the revision of clinical, instrumental and pathologic data of an estimated cohort of maximum 130 patients with NSCLC treated with surgery with radical intent at our center.

Detailed Description
-----------------
This is a retrospective observation that involves the revision of clinical, instrumental and pathologic data of an estimated cohort of 130 patients with NSCLC treated with surgery with radical intent at our center. We will review FDG-PET acquired within 30 days prior to surgery and analyze its principal imaging characteristics with respect to hypoxic and immune-related markers at immunohistochemistry (IHC). These markers will be studied on tumor tissue obtained at surgery, used for diagnostic purposes and stored in paraffin.

Official Title
-----------------
FDG-PET, Marker Immunologici ed Ipossici in Pazienti Affetti da Carcinoma Polmonare Non a Piccole Cellule in Stadio I-III Sottoposti a Chirurgia Radicale

Conditions
-----------------
Carcinoma, Non-Small-Cell Lung

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of NSCLC (Stage I-III) FDG PET before surgery Exclusion Criteria: Absence of tumor specimen No clinical data FDG-PET can not be evaluated

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: No intervention|This is a retrospective study|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation of SUVmax (Maximal Standardized Uptake Value) in patients with non-small cell lung cancer undergoing surgery with hypoxia expression and tumor immune cell infiltration. |  | Baseline SUVmax up to 1 month before surgery. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Carcinoma, Non-Small-Cell Lung, FDG PET, hypoxia markers, immune markers
Patient Positions and Perfusion Index

Study Overview
=================
Brief Summary
-----------------
The association between patient positions including supine,prone, trendelenburg,reverse trendelenburg,45 degrees back up sitting position, 45 degrees legs lifted supine position and perfusion index.

Detailed Description
-----------------
Participants are taken to the recovery room and they will wait 15 minutes until measurements. After monitoring the perfusion index using the right ring finger, first the participant will be taken to supine position. The perfusion index value will be obtained after three minutes of measurement. Second, the position will change to 45 degrees back up sitting position and the measurement will be repeated. Then the participant will be taken to Trendelenburg position, reverse Trendelenburg position, prone, 45 degrees legs lifted supine position respectively, and same measurement will perform.

Official Title
-----------------
The Association Between Surgical Patient Positions and Perfusion Index

Conditions
-----------------
Perfusion

Intervention / Treatment
-----------------
* Other: Perfusion index


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: American society of anesthesiologists score of 1 Exclusion Criteria: any kind of disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patient position<br>Perfusion index | Other: Perfusion index<br>* supine,prone, trendelenburg,reverse trendelenburg,45 degrees back up sitting position, 45 degrees legs lifted supine position.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Perfusion index | Perfusion | one month |
Effect of Fentanyl on Pain Severity and Duration of Labor

Study Overview
=================
Brief Summary
-----------------
Background: There are two methods of pharmacologic and non- pharmacologic for reducing pain of delivery. It is necessary to be known effect of these drugs on the mother and fetus during labor adverse. Therefore, the purpose of this study was determination of effect of Fentanyl intravenously on pain severity during the active phase of labor.

Official Title
-----------------
Principal Investigator

Conditions
-----------------
Decrease Labor Pain

Intervention / Treatment
-----------------
* Drug: Fentanyl


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: multiparas pregnant women (gravid 2-7), term singleton pregnancy, cephalic presentation, low risk pregnancy with no history of drug tolerance (addiction), medical and mental diseases. Exclusion Criteria: Respiratory rate ≤ 8 or maternal bradycardia (pulse rate less than 60).

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 37 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Fentanyl<br>In case group, 50 micrograms fentanyl was prescribed in two doses with an interval of 1 hour. In control group was not intervention. | Drug: Fentanyl<br>* In case group, 50 micrograms fentanyl was prescribed in two doses with an interval of 1 hour after being diluted in 4 cc normal saline<br>|
| No Intervention: Without Fentanyl<br>The control group did not receive Fentanyl. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| decrease pain and duration of the active phase considerably. |  | up to 8 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Fentanyl, analgesia, duration of the active phase, pain severity
A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity

Study Overview
=================
Brief Summary
-----------------
This is a multicenter, randomized, placebo-controlled, double-blind, Phase 2 study. Patients will be treated for a total of 12 weeks. There will be a 6 week follow-up period after the treatment period ends. Patients will be randomly assigned to low dose CJC 1295, high dose CJC 1295 or placebo. The objective is to assess and compare the efficacy, pharmacokinetics, safety, and tolerability of CJC 1295 in patients with human immunodeficiency virus (HIV) associated visceral obesity.

Official Title
-----------------
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 2 Study to Evaluate the Efficacy and Safety of CJC 1295 Administered for 12 Weeks in HIV Infected Patients With HIV Associated Visceral Obesity

Conditions
-----------------
Obesity, HIV Infections

Intervention / Treatment
-----------------
* Drug: CJC 1295


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18-65 on stable antiviral regimen Documented HIV infection HIV associated visceral obesity Body mass index (BMI) > 24 and < 30 kg/m2 Exclusion Criteria: Diabetes Use of growth hormone (GH) or other GH secretagogues Use of systemic glucocorticoids, Use of megestrol acetate or other appetite stimulants, Use of general anorexigenic or weight-reducing agents, or Use of androgens, other than testosterone replacement therapy for male hypogonadism at physiological doses and on a stable regimen for at least 6 months prior to randomization.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: CJC 1295|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Treatment Experienced, HIV Visceral Obesity
Expression of CXCR4 in Patients With Systemic Lupus Erythematosus

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to estimate the possible role of CD184 in the pathogenesis of SLE; comparing its level among SLE cases to healthy controls.

Detailed Description
-----------------
Detection of CXCR4 (CD184) expression on CD19+ B cells by flow cytometry in patients of SLE, comparing its level in the development of lupus activity and pathogenic process of SLE internal organ involvement/ mucocutaneus and/or musculoskeletal involvement. Identify this correlation will be useful for clarifying other accessory factors to improve the diagnosis, better treatment strategy, follow up as well as prognosis for these patients

Official Title
-----------------
Study of CD184 in Systemic Lupus Erythematosus

Conditions
-----------------
Systemic Lupus Erythematosus

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Confirmed SLE patients diagnosed and fulfilled the SLE classification criteria according to the 2019 ACR/EULAR classification criteria for SLE (Aringer et al., 2019) Willing and agreed to be included in the study. Exclusion Criteria: Childhood SLE. SLE-patients will refuse to consent to this study. Other autoimmune diseases. Known or suspected malignancies, especially B cell lymphoma.

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| SLE cases in remission<br>according to SLE Disease Activity Index (SLEDAI) inactive disease will be considered as SLEDAI <5 | |
| SLE cases in activity<br>according to SLE Disease Activity Index (SLEDAI) Active disease will be defined as SLEDAI ≥ 5 | |
| Control group<br>Healthy age and sex matched subjects. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| changes in the expression of CD184(CXCR4) expression in circulating B cells | Flow cytometry analysis of chemokine receptor (CXCR4):Human peripheral-blood mononuclear cells (PBMCs) labeling with CXCR4 antibody will be performed in the same day after taking blood samples and subsequent measurement of the CXCR4 mean fluorescence intensity (MFI) by flow cytometry. MFI of the anti-chemokine receptor (CXCR4) staining will be calculated according to statistical thresholds set in reference to staining with negative control antibodies. The patient's CXCR4 on CD19+ B cells expression or mean MFI will be further compared to the MFI of the simultaneously performed age-matched controls samples and other subgroups of SLE patients. | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CXCR4,CD184,Flow cytometry ,Systemic lupus erythematosus
Reveal LINQ Registry

Study Overview
=================
Brief Summary
-----------------
The Reveal LINQ Registry will generate reliable long-term real world data of product performance, economic valuation, site-of-service procedural information.

Detailed Description
-----------------
The study is a prospective, non-randomized, observational, multi-center, global study. The study will characterize clinical actions initiated by Reveal LINQ arrhythmia detection and estimate procedure-related acute infection rate. Approximately 1,500 subjects will be implanted with a Reveal LINQ ICM and undergo continuous remote monitoring and be followed prospectively from insertion through 36 months.

Official Title
-----------------
Medtronic Reveal LINQ Insertable Cardiac Monitor Registry

Conditions
-----------------
Arrhythmias, Cardiac

Intervention / Treatment
-----------------
* Device: Reveal LINQ


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject or legally authorized representative provides written authorization and/or consent per institution and geographical requirements. Subject is intended to receive or be treated with the have a Reveal LINQ ICM inserted in the next 30 days. Patient enrolled before or on the same date of insertion of the Reveal LINQ ICM Subject consent prior to ICM insertion Exclusion Criteria: Subject who is, or is expected to be inaccessible for follow-up Subject with exclusion criteria required by local law Subject is currently enrolled in or plans to enroll a concurrent study that may confound the results of this study. Co-enrollment in any concurrent drug and/or device clinical study (including registries) requires approval of the study manager or designee.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Reveal LINQ|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number and Type of Clinical Actions Initiated by Reveal LINQ Arrhythmia Detection Feature | Clinical actions taken over the course of study follow-up | Implant to 36 months post-implant | 
| Number of Participants With Procedure-related Acute Infection Rate | Acute infection rate in the subjects who were followed for at least 30 days or had an infection prior to 30 days. Infections are as assessed by the Investigator and defined as deep incision site or superficial infection. Deep incision site are classified as pain, redness, or drainage at incision site requiring the device to be removed or IV antibiotics administered. Superficial infections are defined as redness beyond procedure expectation and oral antibiotics administered. For both deep incision and superficial infections, a physician directed intervention must occur for the event to be defined as an infection. | Implant to 30 days post-implant |
S-ICD French Cohort Study (HONEST)

Study Overview
=================
Brief Summary
-----------------
Implantable cardioverter-defibrillators have been proven to be effective in the prevention of sudden cardiac death in high-risk patients. However, it is well acknowledged that such a strategy could be optimised, especially through new technologies/devices. Data on the entirely sub-cutaneous implantable cardioverter defibrillator (S-ICD) published so far come from high-volume centers and/or selected populations. The HONEST Cohort -taking the opportunity of a unique scenario with a single manufacturer and remote monitoring system available- aims to collect retrospectively baseline information as well as follow-up of all patients implanted with an S-ICD in France since the first implant in October 13, 2012 until December 31, 2019. An extended prospective yearly follow-up will be carried out since January 1, 2020 until December 31, 2024.

Official Title
-----------------
coHOrte fraNcaise Des dEfibrillateurs Sous cuTanés

Conditions
-----------------
Sudden Cardiac Death, Implantable Defibrillator User

Intervention / Treatment
-----------------
* Device: S-ICD


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients who require S-ICD implantation (new or battery replacement) Exclusion Criteria: Refusal of consent

Ages Eligible for Study
-----------------
Minimum Age: 0 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| S-ICD<br> | Device: S-ICD<br>* Implantation of an S-ICD<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ventricular Arrhythmias | Rate of appropriate ICD therapies for ventricular tachycardia / fibrillation | Through study completion, an average of 5 years | 
| Device-Related Complications | Rate of complications related to ICD including inappropriate therapies, infection, lead or generator dysfunction | Through study completion, an average of 5 years | 
| Overall and Specific Mortalities | Overall mortality and causes of death | Through study completion, an average of 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Early Device-Related Complications | Complications occurring within the 3 months following implantation | 3 months | 
| Late Device-Related Complications | Complications occurring after 3 months following implantation | Through study completion, an average of 5 year | 
| Stratified Analyses by Sex, Underlying Heart Disease | Primary and secondary outcomes studied by sex and types of heart diseases | Through study completion, an average of 5 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
outcomes, appropriate shock, complications, subcutaneous